MCP Enters Agreement To Produce Life-Saving Drug

MCP Pharmaceuticals Enters Agreement To Produce Life-Saving Drug

PARSIPPANY, NJ July 06, 2011 — MCP Pharmaceuticals, a leading provider of contract manufacturing services for sterile injectable products has entered into an agreement with an undisclosed pharmaceutical company. The agreement is for the product transfer and registration batch production of a life-saving drug. Commenting on MCP’s selection, Stuart Hinchen, CEO and President of MCP noted, “Our cGMP compliance record and experienced staff allow us to effectively serve this important customer.

MCP’s history of manufacturing DEA- regulated products is vital in producing this terminally sterilized life-saving drug. We see this partnership as another opportunity to demonstrate our customer-focused approach in the manufacture of quality-driven products that save patient lives.” Hinchen also noted, “During the last six months, we successfully completed FDA and EMA audits in addition to entering agreements with four new contract customers.

Our continued investment in our people and our facility has resulted in an internal infrastructure that supports ongoing sustainable growth.” MCP’s Rochester, Michigan manufacturing site has a solid history of successful partnerships, manufacturing clinical and commercial products.

About MCP Pharmaceuticals, LLC

MCP Pharmaceuticals, headquartered in New Jersey, provides contract manufacturing of sterile products including biologics, small molecule, controlled substances, vaccines, ophthalmics, otics and antibiotics for large and small pharmaceutical and biotech organizations. MCP’s sterile manufacturing facility, located in Rochester Michigan sits on over 80 acres of land and includes a 171,000 sq. ft. production building and warehouse.

The production facility utilizes three high-speed filling lines, a clinical filling line and four lyophilizers. The site also includes separate facilities for chemistry, sterility testing, and analytical methods development. MCP has the capability to manufacture small-scale clinical through large-scale commercial products. MCP employs more than 370 staff in the USA in its manufacturing, product development, regulatory, sales and marketing and corporate areas. For more information, please visit jhppharma.com.

Additional Press Releases

04/17/13

MCP Pharmaceuticals To Produce Supplies of Biologic Drug Product For Late-Phase Clinical Trials

Webpage | PDF Format

12/31/12

MCP Pharmaceuticals Acquired By Warburg Pincus

Webpage | PDF Format

09/19/12

MCP Pharmaceuticals To Produce Lyophilized Biologic for International Late-Phase Clinical Trials

Webpage | PDF Format

06/07/12

MCP Pharmaceuticals Launches Generic Division